These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 21855604)

  • 1. Distribution and pharmacological characterization of primate NK-2 tachykinin receptor in the central nervous system of the rhesus monkey.
    Nagano M; Oishi T; Suzuki H
    Neurosci Lett; 2011 Sep; 503(1):23-6. PubMed ID: 21855604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distribution and pharmacological characterization of primate NK-1 and NK-3 tachykinin receptors in the central nervous system of the rhesus monkey.
    Nagano M; Saitow F; Haneda E; Konishi S; Hayashi M; Suzuki H
    Br J Pharmacol; 2006 Feb; 147(3):316-23. PubMed ID: 16331282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasopressin release from the rat hypothalamo-neurohypophysial system: effects of tachykinin NK-1 and NK-2 receptors agonists and antagonists.
    Juszczak M
    Neuro Endocrinol Lett; 2005 Aug; 26(4):367-72. PubMed ID: 16136007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists.
    Sundqvist M; Kristensson E; Adolfsson R; Leffler A; Ahlstedt I; Engberg S; Drmota T; Sigfridsson K; Jussila R; de Verdier J; Novén A; Johansson A; Påhlman I; von Mentzer B; Lindström E
    Eur J Pharmacol; 2007 Dec; 577(1-3):78-86. PubMed ID: 17920583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NK1 receptor-mediated endothelium-dependent relaxation and contraction with different sensitivity to post-receptor signaling in pulmonary arteries.
    Miike T; Shirahase H; Kanda M; Kunishiro K; Kurahashi K
    Vascul Pharmacol; 2009; 51(2-3):147-53. PubMed ID: 19539781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics.
    Dawson LA; Langmead CJ; Dada A; Watson JM; Wu Z; de la Flor R; Jones GA; Cluderay JE; Southam E; Murkitt GS; Hill MD; Jones DN; Davies CH; Hagan JJ; Smith PW
    Eur J Pharmacol; 2010 Feb; 627(1-3):106-14. PubMed ID: 19879867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tachykinin receptor expression and function in human esophageal smooth muscle.
    Kovac JR; Chrones T; Preiksaitis HG; Sims SM
    J Pharmacol Exp Ther; 2006 Aug; 318(2):513-20. PubMed ID: 16714401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological evaluation of alpha and beta human tachykinin NK(2) receptor splice variants expressed in CHO cells.
    Bellucci F; Meini S; Catalioto RM; Catalani C; Giuliani S; Quartara L; Giolitti A; Faiella A; Rotondaro L; Candenas ML; Pinto FM; Maggi CA
    Eur J Pharmacol; 2004 Sep; 499(3):229-38. PubMed ID: 15381044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation and pharmacological characterization of a hamster urinary bladder neurokinin A receptor cDNA.
    Aharony D; Little J; Thomas C; Powell S; Berry D; Graham A
    Mol Pharmacol; 1994 Jan; 45(1):9-19. PubMed ID: 8302285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel triple neurokinin receptor antagonist CS-003 strongly inhibits neurokinin related responses.
    Tsuchida H; Takahashi S; Nosaka E; Mukaiyama O; Yamashita M; Morimoto K
    Eur J Pharmacol; 2008 May; 586(1-3):306-12. PubMed ID: 18353309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.
    Rumsey WL; Aharony D; Bialecki RA; Abbott BM; Barthlow HG; Caccese R; Ghanekar S; Lengel D; McCarthy M; Wenrich B; Undem B; Ohnmacht C; Shenvi A; Albert JS; Brown F; Bernstein PR; Russell K
    J Pharmacol Exp Ther; 2001 Jul; 298(1):307-15. PubMed ID: 11408556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist.
    Sarau HM; Griswold DE; Bush B; Potts W; Sandhu P; Lundberg D; Foley JJ; Schmidt DB; Webb EF; Martin LD; Legos JJ; Whitmore RG; Barone FC; Medhurst AD; Luttmann MA; Giardina GA; Hay DW
    J Pharmacol Exp Ther; 2000 Oct; 295(1):373-81. PubMed ID: 10992004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxytocin release from the rat neurohypophysis into the blood: effects of tachykinin NK-1 and NK-2 receptors agonists and antagonists.
    Juszczak M; Boczek-Leszczyk E
    J Physiol Pharmacol; 2008 Sep; 59(3):553-62. PubMed ID: 18953097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Point mutation increases a form of the NK1 receptor with high affinity for neurokinin A and B and septide.
    Ciucci A; Palma C; Manzini S; Werge TM
    Br J Pharmacol; 1998 Sep; 125(2):393-401. PubMed ID: 9786514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Species differences in tachykinin receptor distribution: further evidence that the substance P (NK1) receptor predominates in human brain.
    Rigby M; O'Donnell R; Rupniak NM
    J Comp Neurol; 2005 Oct; 490(4):335-53. PubMed ID: 16127708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Localization and function of NK(3) subtype tachykinin receptors of layer V pyramidal neurons of the guinea-pig medial prefrontal cortex.
    Simmons MA; Sobotka-Briner CD; Medd AM
    Neuroscience; 2008 Oct; 156(4):987-94. PubMed ID: 18801417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MEN 11420 (Nepadutant), a novel glycosylated bicyclic peptide tachykinin NK2 receptor antagonist.
    Catalioto RM; Criscuoli M; Cucchi P; Giachetti A; Gianotti D; Giuliani S; Lecci A; Lippi A; Patacchini R; Quartara L; Renzetti AR; Tramontana M; Arcamone F; Maggi CA
    Br J Pharmacol; 1998 Jan; 123(1):81-91. PubMed ID: 9484857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of melatonin on the vasopressin secretion as influenced by tachykinin NK-1 receptor agonist and antagonist: in vivo and in vitro studies.
    Juszczak M; Boczek-Leszczyk E; Stempniak B
    J Physiol Pharmacol; 2007 Dec; 58(4):829-43. PubMed ID: 18195491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tachykinin activation of human monocytes from patients with interstitial lung disease, healthy smokers or healthy volunteers.
    Brunelleschi S; Nicali R; Lavagno L; Viano I; Pozzi E; Gagliardi L; Ghio P; Albera C
    Neuropeptides; 2000 Feb; 34(1):45-50. PubMed ID: 10688968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology of MEN 11467: a potent new selective and orally- effective peptidomimetic tachykinin NK(1) receptor antagonist.
    Cirillo R; Astolfi M; Conte B; Lopez G; Parlani M; Sacco G; Terracciano R; Fincham CI; Sisto A; Evangelista S; Maggi CA; Manzini S
    Neuropeptides; 2001; 35(3-4):137-47. PubMed ID: 11884203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.